TROP2-ADC F0024(FDA018)首次人体I期剂量递增及三阴性乳腺癌扩展研究
这项首次人体I期研究评估了TROP2导向ADC F0024在晚期实体瘤中的安全性和耐受性,并在经重度治疗的三阴性乳腺癌患者中进行剂量扩展。研究纳入67例受试者,剂量递增至15 mg/kg时因累积毒性担忧而停止,10 mg/kg组在TNBC中客观缓解率达37.9%、中位无进展生存期10.5个月,推荐II期剂量为10 mg/kg。
要点
- F0024在TNBC中显示抗肿瘤活性,10 mg/kg组ORR为37.9%、中位PFS为10.5个月。
- TNBC扩展队列中≥3级治疗相关不良事件发生率为57.7%,严重TRAE为9.6%。
- 推荐II期剂量(RP2D)为10 mg/kg,血液学毒性常见但可管理。
核心结论
- F0024在TNBC中显示出有前景的抗肿瘤活性,血液学毒性常见但可管理,RP2D为10 mg/kg。
研究设计与样本
- 首次人体、I期剂量递增及TNBC剂量扩展研究(NCT05174637),共纳入67例受试者,其中剂量递增26例、TNBC扩展41例。
- 剂量递增阶段F0024静脉给药剂量范围为2.5-15 mg/kg,TNBC扩展队列接受10或12 mg/kg。
主要发现
- 剂量递增阶段发生2例剂量限制性毒性,15 mg/kg因累积毒性担忧而停止递增。
- 剂量递增队列中≥3级TRAE发生率为56.0%,且随剂量增加而升高。
- 从5 mg/kg起观察到显著抗肿瘤活性,10 mg/kg组ORR为66.7%。
- TNBC人群中10 mg/kg组ORR为37.9%、中位PFS为10.5个月;12 mg/kg组ORR为23.5%、PFS为4.3个月。
- TNBC汇总人群中≥3级TRAE发生率为57.7%,严重TRAE报告率为9.6%。
关键数值与推荐
- RP2D为10 mg/kg。
- TNBC扩展队列中10 mg/kg组ORR为37.9%、中位PFS为10.5个月;12 mg/kg组ORR为23.5%、PFS为4.3个月。
- TNBC汇总人群中≥3级TRAE发生率为57.7%,严重TRAE为9.6%。
临床怎么用
- F0024在经重度治疗的TNBC中显示出活性,支持以10 mg/kg作为RP2D进一步开发。
- 临床使用时需关注血液学毒性及剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This first-in-human, phase I study (NCT05174637) assessed F0024 (FDA018), a TROP2-directed ADC, in advanced solid tumors, including a dose-expansion cohort in triple-negative breast cancer (TNBC). METHODS: Participants were intravenously administered F0024 (2.5-15 mg/kg) in the dose-escalation phase to determine the safety and tolerability. Dose-expansion cohorts of patients with heavily pretreated TNBC received doses of 10 or 12 mg/kg to further assess the efficacy and safety. RESULTS: 67 participants were enrolled (26 in dose-escalation and 41 in TNBC expansion). Two dose-limiting toxicities occurred. Dose escalation was halted at 15 mg/kg due to cumulative toxicity concerns. Across escalation cohorts, grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% and increased with dose. Notable antitumor activity was observed from 5 mg/kg, with an objective response rate (ORR) of 66.7% in the 10 mg/kg group. In the TNBC population, 10 mg/kg achieved an ORR of 37.9% and a median PFS of 10.5 months; 12 mg/kg showed an ORR of 23.5% and a PFS of 4.3 months. Grade ≥ 3 TRAEs occurred in 57.7% of the pooled TNBC population; serious TRAEs were reported in 9.6%. CONCLUSION: F0024 demonstrated promising antitumor activity in TNBC, with manageable but frequent hematologic toxicity and dose modifications. The recommended phase II dose (RP2D) is 10 mg/kg.
引用
- Du Y, Meng Y, Liu X, et al. A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). Eur J Cancer. 2026. PMID: 42810148. doi:10.1016/j.ejca.2026.117063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。